Homespun AHF Ad Campaigns Target HIV Stigma, STD Testing
The parallel, but visually different, campaigns each feature artwork with homespun feel coupled with a simple and straightforward message intended to both catch and challenge a viewer's attention, but then bring them closer to the intended message. The two campaigns will appear in nearly three dozen cities and regions across the U.S. where AHF provides care and services and will run for the next three months.
The first campaign, 'HIV Stigma Sucks,' is a reboot of an earlier and popular outdoor AHF campaign. The scratch-your-head homespun twist here: The artwork features the simple three-word tagline, HIV Stigma Sucks, rendered in the old-time style of an embroidered sampler that one might find hanging on a grandmother's wall or gracing a pillow cover on her overstuffed davenport sofa. The artwork also features a red ribbon and drives to the URL, HIVcare.org, where individuals facing stigma and limited access to affirming healthcare can learn about and book an appointment with an AHF HIV specialist.
The other campaign, 'Testing is Caring,' takes a more modern approach featuring contemporary photographs of upbeat, smiling same-sex male couples bookended by the tagline, 'Testing is Caring.' Again, the simple artwork here drives to the URL freeSTDcheck.org. The homespun hook here is the artwork's down-to-earth declaration that something as simple as routine medical testing can be, or is a demonstration of care for oneself and one's partners.
The 'Testing is Caring' outdoor advertisements started posting last week on billboards, bus interior cards, bus benches, posters, and transit shelters. The campaign will appear nationwide in 34 cities in 14 states, Washington, DC and Puerto Rico where AHF has clinics and Wellness Centers offering free STD testing and treatment, including in CALIFORNIA: Los Angeles, Oakland, San Diego & San Francisco; FLORIDA: Delray Beach, Ft. Lauderdale, Ft. Meyers, Hialeah, Jacksonville, Liberty City, Miami, Orlando, Pensacola, South Beach, St. Petersburg and West Palm Beach; GEORGIA: Atlanta; ILLINOIS: Chicago; LOUISIANA: Baton Rouge and New Orleans; MARYLAND, Baltimore; MISSISSIPPI: Jackson; NEW YORK: Bronx and Queens; NEVADA: Las Vegas; OHIO: Cleveland and Columbus; PENNSYLVANIA: Philadelphia; SOUTH CAROLINA: Columbia; TEXAS: Dallas, Houston, and Ft. Worth; and WASHINGTON: Seattle; WASHINGTON, DC and in PUERTO RICO. This campaign also appears in Spanish headlined, 'la prueba es cariño," and drives to the URL pruebasdeITSgratuitas.org.
The 'HIV Stigma Sucks' outdoor advertisements started posting last week on billboards, bus interior cards, bus benches, posters, and transit shelters. The campaign will appear nationwide in 34 cities in 14 states and Washington, DC where AHF has clinics and Wellness Centers offering free STD testing and treatment, including in CALIFORNIA: Los Angeles, Oakland, San Diego & San Francisco; FLORIDA: Delray Beach, Ft. Lauderdale, Ft. Meyers, Hialeah, Jacksonville, Liberty City, Miami, Orlando, Pensacola, South Beach, St. Petersburg and West Palm Beach; GEORGIA: Atlanta; ILLINOIS: Chicago; LOUISIANA: Baton Rouge and New Orleans; MARYLAND, Baltimore; MISSISSIPPI: Jackson; NEW YORK: Bronx, Brooklyn and Queens; NEVADA: Las Vegas; OHIO: Cleveland and Columbus; PENNSYLVANIA: Philadelphia; SOUTH CAROLINA: Columbia; TEXAS: Dallas, Houston, and Ft. Worth; and WASHINGTON: Seattle; and WASHINGTON, DC.
AIDS Healthcare Foundation (AHF), the world's largest HIV/AIDS healthcare organization, provides cutting-edge medicine and advocacy to more than 2.4 million individuals across 48 countries, including the U.S. and in Africa, Latin America/Caribbean, the Asia/Pacific Region, and Eastern Europe. In January 2025, AHF received the MLK, Jr. Social Justice Award, The King Center's highest recognition for an organization leading work in the social justice arena. To learn more about AHF, visit us online at AIDShealth.org, find us on Facebook, and follow us on Instagram, Twitter, and TikTok.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Health Line
11 hours ago
- Health Line
What Is Rupioid Psoriasis?
Rupioid psoriasis is a type of psoriasis that causes thick plaques that may resemble barnacles or oyster shells. It's rare, but it may cause severe symptoms for some people. Psoriasis is an autoimmune disease that causes rashes that are often itchy and scaly. The most common type, plaque psoriasis, is characterized by raised and red patches of skin. Rupioid psoriasis is a type of plaque psoriasis. Some people with rupioid psoriasis develop severely itchy or painful plaques that can cover large areas of the body, such as the back or limbs. Due to the thickness of the plaques, it can be challenging to treat with creams, but many people have relief with medications taken in other ways, such as injections. Learn more about rupioid psoriasis, such as potential causes, symptoms, and treatment options. Rupioid psoriasis causes and risk factors Rupioid psoriasis is a rare type of plaque psoriasis. It's frequently associated with immunosuppressive conditions like HIV. Doctors don't know the exact cause of plaque psoriasis, but it's thought to develop when your immune system starts attacking healthy skin cells. This autoimmune reaction can cause inflammation and the formation of plaques. Rupioid psoriasis seems to occur more frequently in males than females and is particularly rare among children. Psoriasis is thought to develop due to a combination of factors, including genetics and environmental factors. People with direct family history of psoriasis seem to be more likely to develop it, too. Plaque psoriasis often develops after a previous skin injury, such as: cuts scrapes insect bites sunburns Symptoms often appear after exposure to a certain trigger. Along with skin injuries, common triggers include: stress infections frequent or excessive alcohol consumption weather changes like changes in humidity smoking alcohol sunlight some medications »MORE: These are the most common psoriasis triggers. Psoriasis and medications Psoriasis flare-ups have been linked to many types of medications, such as: beta-blockers antimalarial drugs bupropion calcium channel blockers captopril fluoxetine lithium penicillin terbinafine interferons interleukins fluoxetine glyburide granulocyte colony-stimulating factor Rupioid psoriasis symptoms Rupioud psoriasis and other forms of plaque psoriasis cause raised plaques of skin that usually have a silvery and crusted layer over them. Unlike other forms of plaque psoriasis, the characteristic sign of rupioid psoriasis is thick and crusty plaques that resemble oyster shells or barnacles. Plaques may also: cause pinpoint bleeding when the area is scraped (Auspitz sign) be a darker color than plaques caused by other types of psoriasis have well-defined borders Plaques can occur anywhere, but often occur on your: torso scalp knees elbows arms legs Rupioid psoriasis pictures Here are some examples of rupioid psoriasis. Note the barnacle or oyster shell-like appearance of the plaques. Potential complications of rupioid psoriasis People with rupioid psoriasis seem to be particularly prone to developing a complication called psoriatic arthritis. Psoriatic arthritis can cause symptoms like: joint pain and tenderness swollen joints joint stiffness reduced range of motion warmth in your joints People with psoriasis may also be at an increased risk of developing some other conditions, such as: cardiovascular disease eye inflammation (uveitis) some other autoimmune conditions »MORE: These are the potential complications of psoriasis. When to get medical help It's important to seek medical help if you develop potential symptoms of psoriasis, such as unexplained rashes or itchiness. It's also important to visit your doctor if you've previously been diagnosed but you develop new or worsening symptoms. Your doctor can recommend how to reduce your symptoms and tell you if you may benefit from treatments like prescription medications to reduce your symptoms. »FIND CARE: Find a dermatologist in your area today. Rupioid psoriasis diagnosis The initial step to getting a psoriasis diagnosis usually involves visiting your primary healthcare professional. They will ask you questions about your symptoms, review your medical history, and examine your skin during your initial appointment. They may highly suspect psoriasis based on the appearance of your plaques. To confirm the diagnosis, they may take a small sample of your skin called a biopsy so that it can be examined under a microscope. They may refer you to a doctor who specializes in conditions of the skin and hair, called a dermatologist. Rupioid psoriasis treatment The best treatment for you depends on the severity of your symptoms. Your doctor may suggest trying medicated anti-inflammatory creams. However, rupioid psoriasis can be particularly hard to treat with topical options because the thick plaques may make it difficult for them to penetrate your skin. Your doctor may prescribe oral medications or medications administered through injection in combination with topical medications to reduce immune system activity. These medications may include: methotrexate cyclosporine ustekinumab steroids Can you prevent rupioid psoriasis? It's not always possible to prevent psoriasis, but you may be able to reduce your number of flare-ups by avoiding your triggers. Many people find it helpful to carry a journal or keep a list on their phone tracking when their flare-ups occurred and which factors might have contributed. Living with rupioid psoriasis Psoriasis doesn't have a cure, but receiving proper treatment can help you keep your symptoms under control. Psoriasis often comes in flare-ups. Identifying your triggers and figuring out when your symptoms get worse is important for anybody living with psoriasis. You may have to try several treatment options before you find one that's effective for you. But many people are eventually able to keep their symptoms under control. Takeaway Rupioid psoriasis is a rare but often severe form of psoriasis that causes plaques that may resemble oyster shells or barnacles. These plaques can become very itchy or painful. It's important to speak with a doctor if you think you may have psoriasis or if you think your psoriasis is getting worse. They may recommend trying treatment options like prescription creams or medications administered through injections.
Business Wire
13 hours ago
- Business Wire
Exicure Completes the Last Patient, Last Visit in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced it has completed the last patient, last visit in its ongoing Phase 2 clinical trial (NCT05561751) evaluating the safety and efficacy of GPC-100 (burixafor) in combination with propranolol and G-CSF in multiple myeloma patients undergoing autologous stem cell transplant (ASCT). Topline results from the study are expected in the fourth quarter of 2025. The randomized, open-label, multicenter study is designed to assess whether GPC-100, a small molecule CXCR4 antagonist, can improve CD34+ hematopoietic stem cell mobilization from the bone marrow into the peripheral blood, where they can be collected via leukapheresis for use in ASCT. In data presented at ASH 2024, GPC-100 appears to be well differentiated in terms of the speed with which it mobilizes stem cells compared to currently approved stem cell mobilization treatments. Dr. Muthalagu Ramanathan, Director of the Myeloma Program and Medical Co-Director of the Blood and Marrow Transplant and CAR-T Program at U Mass Memorial Health noted that 'traditionally, patients undergoing mobilization are required to come, as an outpatient, the night before their procedure to receive the mobilization injection — a process that adds logistical challenges. The study drug GPC100 needed to be administered just 45 minutes before stem cell collection and resulted in a successful mobilization, significantly improving the patient experience. This is a true blessing for our frail myeloma patients.' In addition to multiple myeloma and a planned Phase 1 study in acute myeloid leukemia (AML) patients, the company is also in discussions for potential collaborations that would utilize GPC-100's rapid and safe mobilization of stem cells in cell and gene therapy settings. About GPC-100 GPC-100 (burixafor) is a highly selective small molecule antagonist of CXCR4, a chemokine receptor that plays a central role in retaining hematopoietic stem cells in the bone marrow niche. By blocking CXCR4, GPC-100 may enhance the mobilization of these cells into the peripheral blood for collection and use in autologous stem cell transplant (ASCT) procedures. Originally developed by GPCR Therapeutics, Inc., GPC-100 became part of Exicure's pipeline following the company's acquisition in January 2025. In addition to multiple myeloma, GPC-100 is also being considered in acute myeloid leukemia (AML) and other diseases where improved stem cell mobilization could help enable more efficient and effective treatment approaches, such as sickle cell disease, rare diseases requiring autologous transplant, and cell and gene therapy settings. About Exicure Exicure, Inc. (Nasdaq: XCUR) is a clinical-stage biotechnology company developing therapies to address key challenges in hematologic diseases. The company's lead program, GPC-100, is being evaluated for its ability to improve stem cell mobilization in multiple myeloma, sickle cell disease, and in support of cell and gene therapy. It is also being studied as a potential chemosensitizing agent in acute myeloid leukemia (AML). For more information, visit
Yahoo
14 hours ago
- Yahoo
Genentech's Susvimo Maintains Vision Over Five Years With Two Refills Per Year in People With Wet Age-Related Macular Degeneration (AMD)
– Susvimo is the only continuous delivery treatment to provide reliable, long-term vision outcomes in wet AMD, the leading cause of vision loss in people over the age of 60 – – With two refills per year, Susvimo maintained vision and stabilized the retina for five years, with durability maintained in approximately 95% of patients – – Susvimo was well tolerated over five years and has a well-characterized safety profile – SOUTH SAN FRANCISCO, Calif., August 01, 2025--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today new, five-year efficacy, safety and durability data from the Phase III Portal study, a long-term extension of the Phase III Archway study, of Susvimo® (ranibizumab injection) for the treatment of people with wet AMD. Results show that Susvimo's immediate and predictable durability was sustained over five years, with approximately 95% of people receiving treatment every six months requiring no supplemental treatment before each refill. The data were presented at the American Society of Retina Specialists (ASRS) 2025 Annual Meeting in Long Beach, California. "These long-term results reinforce Susvimo's ability to maintain vision and retinal drying over a long period of time for people with wet AMD, the leading cause of vision loss in people over age 60," said Levi Garraway, M.D., Ph.D., Genentech's chief medical officer and head of Global Product Development. "These robust data reinforce our confidence in Susvimo's unique therapeutic approach, providing an effective alternative to regular eye injections while preserving vision in a sustained manner." "People with wet AMD often experience suboptimal outcomes with real-world anti-VEGF treatment, largely due to the frequency of injections," said study investigator John Kitchens, M.D., Retina Associates of Kentucky, who presented the data at ASRS. "Continuous delivery of treatment with Susvimo may preserve vision in patients with wet AMD for longer in real-world clinical use than IVT injections." In the Portal study (n = 352), people originally treated with Susvimo in Archway continued to receive Susvimo refills every six months (Susvimo cohort; n = 220), while those originally treated with monthly intravitreal (IVT) ranibizumab injections in Archway received Susvimo and then refills every six months (IVT-Susvimo cohort; n = 132). Five-year results showed consistent and sustained disease control and retinal drying in a population who entered Archway with vision at or near peak levels after receiving an average of five intravitreal injections per standard of care. In the Susvimo cohort, best-corrected visual acuity (BCVA) was 74.4 letters at baseline and 67.6 letters at 5 years. In the IVT-Susvimo cohort, BCVA was 76.3 letters at baseline and 68.6 at 5 years. Half of all patients had better than 20/40 vision at five years (Snellen visual acuity test). Average central subfield thickness (CST) remained stable, with a 1.0 (95% CI: -13.1, 11.1) µm reduction from baseline in the Susvimo cohort, and a 10.3 (95% CI: -25.7, 5.0) µm reduction in the IVT-Susvimo cohort. The cohort of people who entered the Portal study from Archway is the largest cohort of people with wet AMD to be followed prospectively and continuously for five years in a clinical study. Susvimo provides continuous delivery of a customized formulation of ranibizumab via the Port Delivery Platform, while other currently approved treatments may require eye injections as often as once per month. The Port Delivery Platform is a refillable eye implant surgically inserted into the eye during a one-time, outpatient procedure, which introduces medicine directly into the eye, addressing certain retinal conditions that can cause vision loss. About the Archway study and its open-label extension study (Portal) Archway (NCT03677934) was a randomized, multicenter, open-label Phase III study evaluating the efficacy and safety of Susvimo refilled every six months at fixed intervals, compared to monthly IVT ranibizumab 0.5 mg in 415 people living with wet AMD. Patients were randomized 3:2 to Susvimo (n = 248) or intravitreal (IVT) ranibizumab injections (n = 167). Patients enrolled in Archway were responders to prior treatment with anti-VEGF therapy. In both study arms, patients were treated with at least three anti-VEGF injections within the six months prior to their Archway screening visit, with an average of five anti-VEGF injections before randomization. The primary endpoint of the study was the change in BCVA score from baseline at the average of Week 36 and Week 40. Secondary endpoints include safety, overall change in vision (BCVA) from baseline and change from baseline in center point thickness over time. Patients who completed the study at week 96 were eligible to enter the Portal open-label extension study. In Portal, people originally treated with Susvimo in Archway continued to receive Susvimo refills every six months (Susvimo cohort), while those originally treated with monthly IVT ranibizumab injections in Archway received the Susvimo implant and then refills every six months (IVT-Susvimo cohort). Portal is ongoing. About Wet Age-Related Macular Degeneration (AMD) Age-related macular degeneration (AMD) is a condition that affects the macula, the part of the eye that provides sharp, central vision needed for activities like reading. It is a leading cause of blindness for people aged 60 and over in the U.S. Wet, or neovascular, AMD is an advanced form of the disease that can cause rapid and severe vision loss. Approximately 20 million people in the U.S. have some form of AMD, and of those, about 1.5 million have late-stage AMD, which includes wet AMD. Wet AMD is caused by growth of abnormal blood vessels, also referred to as choroidal neovascularization (CNV), into the macula. These vessels leak fluid and blood and cause scar tissue that destroys the central retina. This process results in a deterioration of sight over a period of months to years. Genentech is committed to helping people access the medicines they are prescribed and offers comprehensive services for people prescribed Susvimo to help minimize barriers to access and reimbursement. Patients can call 833-EYE-GENE for more information. For people who qualify, Genentech offers patient assistance programs through Genentech Access Solutions. More information is also available at (866) 4ACCESS/(866) 422-2377 or Visit for additional information. About Susvimo® (ranibizumab injection) 100 mg/mL for intravitreal use via ocular implant Susvimo® (ranibizumab injection) 100 mg/mL for intravitreal use via ocular implant is a refillable implant surgically inserted into the eye during a one-time, outpatient procedure. Susvimo continuously delivers a customized formulation of ranibizumab over time. Susvimo is indicated for intravitreal use via the Susvimo eye implant only. Ranibizumab is a vascular endothelial growth factor (VEGF) inhibitor designed to bind to and inhibit VEGF-A, a protein that has been shown to play a critical role in the formation of new blood vessels and the leakiness of the vessels. Susvimo was previously called the Port Delivery System with ranibizumab in the U.S. The customized formulation of ranibizumab delivered by Susvimo is different from the ranibizumab intravitreal injection, a medicine marketed as Lucentis® (ranibizumab injection), which is approved to treat wet, or neovascular, age-related macular degeneration (AMD) and other retinal diseases. Lucentis was first approved for wet AMD by the FDA in 2006. Susvimo Indication Susvimo (ranibizumab injection) 100 mg/mL for intravitreal use via ocular implant is indicated for the treatment of patients with neovascular (wet) age-related macular degeneration (AMD), diabetic macular edema (DME), and diabetic retinopathy (DR) who have previously responded to at least two intravitreal injections of a vascular endothelial growth factor inhibitor medication. Susvimo Important Safety Information WARNING: ENDOPHTHALMITISThe Susvimo implant has been associated with an up to 3-fold higher rate of endophthalmitis than monthly intravitreal injections of ranibizumab. Warnings and Precautions:The Susvimo implant and the procedures associated with inserting, filling, refilling, and (if medically necessary) removing the implant can cause other serious side effects, including: An eye infection (endophthalmitis). Endophthalmitis is an infection of the eyeball that can cause permanent damage to your eye, including blindness. Endophthalmitis requires urgent (same-day) medical or surgical treatment. A missing layer on top of the white part of the eye (conjunctival erosion). Conjunctival erosion is an area that becomes missing (defect) in the layer (conjunctiva) that covers the white part of the eye, which may result in exposure of the implant. Conjunctival erosion may require surgical treatment. An opening of the layer that covers the white part of the eye (conjunctival retraction). Conjunctival retraction is an opening or gaping in the layer (conjunctiva) that covers the white part of the eye, which may cause the implant to be exposed. Conjunctival retraction may require surgical treatment. Tear and separation of layers of the retina (rhegmatogenous retinal detachment). Rhegmatogenous retinal detachment is a tear and separation of one of the layers of the retina in the back of the eye that senses light. Rhegmatogenous retinal detachment requires surgical treatment. Implant movement (implant dislocation): This movement may require surgical treatment to correct. Implant damage: Damage to the implant that prevents continued treatment (refills) with Susvimo. If the implant is not able to be properly refilled, a patient's wet AMD may be inadequately treated and a physician may remove the implant and/or change the treatment. Bleeding (vitreous hemorrhage): Vitreous hemorrhage is bleeding within the gel-like substance (vitreous) inside of your eye. This may require an additional eye surgery. Bump on top of the white layer of the eye (conjunctival bleb): Conjunctival bleb is a small bulge in the layer (conjunctiva) that covers the white part of the eye where the implant is inserted. This may be due to leakage of fluid from the inside of the eye. This may require medical or surgical treatment. Temporary decrease in vision after the Susvimo procedure. Who should not receive Susvimo? Patients who have an infection in or around their eye, have active inflammation in their eye, or have had an allergic reaction to ranibizumab or any of its ingredients in Susvimo in the past. Information for patients who are of childbearing potential If patients are pregnant, think that they might be pregnant, or plan to become pregnant. It is not known if Susvimo will harm an unborn baby. Patients should use birth control (contraception) during treatment with Susvimo and for 12 months after the last refill of Susvimo. If patients are breastfeeding or plan to breastfeed. Susvimo is not recommended during breastfeeding. It is not known if Susvimo passes into breast milk. Adverse Reactions The most common adverse reactions were blood on the white of the eye, redness in the white of the eye, sensitivity to light, and eye pain. These are not all the possible side effects of Susvimo. You may report side effects to the FDA at (800) FDA-1088 or You may also report side effects to Genentech at (888) 835-2555. Please see additional Important Safety Information in the full Susvimo Prescribing Information, including BOXED WARNING or visit About Lucentis® (ranibizumab injection) Lucentis® is a vascular endothelial growth factor (VEGF) inhibitor designed to bind to and inhibit VEGF-A, a protein that is believed to play a critical role in the formation of new blood vessels (angiogenesis) and the hyperpermeability (leakiness) of the vessels. Lucentis is FDA-approved for the treatment of patients with wet age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), diabetic retinopathy (DR) and myopic choroidal neovascularization (mCNV). Lucentis was developed by Genentech, a member of the Roche Group. The company retains commercial rights in the United States and Novartis has exclusive commercial rights for the rest of the world. Outside the United States, Lucentis is approved in more than 120 countries to treat adult patients with wet AMD, and for the treatment of visual impairment due to DME, due to macular edema secondary to both branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO), and due to choroidal neovascularization (CNV). Lucentis Important Safety Information Lucentis is contraindicated in patients with ocular or periocular infections or known hypersensitivity to ranibizumab or any of the excipients in Lucentis. Hypersensitivity reactions may manifest as severe intraocular inflammation. Intravitreal injections, including those with Lucentis, have been associated with endophthalmitis, retinal detachment, and iatrogenic traumatic cataract. Increases in intraocular pressure have been noted both pre-injection and post-injection with Lucentis. Although there was a low rate of arterial thromboembolic events (ATEs) observed in the Lucentis clinical trials, there is a potential risk of ATEs following intravitreal use of VEGF inhibitors. ATEs are defined as nonfatal stroke, nonfatal myocardial infarction, or vascular death (including deaths of unknown cause). Fatal events occurred more frequently in patients with DME and DR at baseline treated monthly with Lucentis compared with control. Although the rate of fatal events was low and included causes of death typical of patients with advanced diabetic complications, a potential relationship between these events and intravitreal use of VEGF inhibitors cannot be excluded. Retinal vasculitis and/or retinal vascular occlusion have been reported. Patients should be instructed to report any change in vision without delay. In the Lucentis Phase III clinical trials, the most common ocular side effects included conjunctival hemorrhage, eye pain, vitreous floaters, and increased intraocular pressure. The most common non-ocular side effects included nasopharyngitis, anemia, nausea, and cough. You may report side effects to the FDA at (800) FDA-1088 or You may also report side effects to Genentech at (888) 835-2555. For additional safety information, please see Lucentis full Prescribing Information, available here: About Genentech in Ophthalmology Genentech is researching and developing new treatments for people living with a range of eye diseases that cause significant visual impairment and blindness, including wet age-related macular degeneration (AMD), diabetic macular edema (DME), diabetic retinopathy (DR), geographic atrophy (GA) and other retinal diseases, including rare and inherited conditions. About Genentech Founded more than 40 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious and life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California. For additional information about the company, please visit View source version on Contacts Media Contact:Nicole Burkart (650) 467-6800Advocacy Contact:Meg Harrison (617) 694-7060Investor Contacts:Loren Kalm (650) 225-3217Bruno Eschli +41 61 687 5284 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
